Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Items 301–400 of 999
Menon, R., Zhang, Q., Zhang, Y., Fermin, D., Bardeesy, N., DePinho, R. A., Lu, C., Hanash, S. M., Omenn, G. S., & States, D. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2145 · Cited by 74
“The Kras G12D / Ink4a/Arf mouse model of PDAC was engineered with signature mutations that recapitulate the histopathologic progression of the human disease in a highly reproducible and synchronous fashion (9, 10).”
MethodInfluentialSelf-citationRowley, M., Ohashi, A., Mondal, G., Mills, L., Yang, L., Zhang, L., Sundsbak, R. S., Shapiro, V. S., Muders, M. H., Smyrk, T. C., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.12.039 · Cited by 86
mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Driscoll, D. R., Karim, S. A., Sano, M., Gay, D. M., Jacob, W., Yu, J., Mizukami, Y., Gopinathan, A., Jodrell, D. I., Evans, T. R. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0810 · Cited by 74
“13 The cyclin dependent kinase (CDK) inhibitor p16Ink4a has been proposed as a barrier to KRAS-driven PDAC development (32).”
BackgroundSelf-citationOlson, P., Chu, G. C., Perry, S. R., Nolan-Stevaux, O., & Hanahan, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111079108 · Cited by 73
Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Singh, M., Couto, S. S., Forrest, W. F., Lima, A., Cheng, J. H., Molina, R., Long, J. E., Hamilton, P., McNutt, A., Kasman, I., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4053 · Cited by 71
Estrada‐Bernal, A., Chatterjee, M., Haque, S. J., Yang, L., Morgan, M. A., Kotian, S., Morrell, D., Chakravarti, A., & Williams, T. M. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1104437 · Cited by 77
“the growth, survival and migration of pancreatic cancer cells.(8,9) The oncogenic mutant KRAS also activates the PI3K-AKT/ mTOR pathway that plays many critical roles in tumorigenesis.”
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 82
“6 essential actor to their survival and progress although a slow evolution that requires additional genetic events such as Trp53, Ink4a/ARF, Smad4 tumor suppressor mutations to form invasive adenocarcinoma (25-29).”
BackgroundSPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity
Rivera, L. B., & Brekken, R. A. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201011143 · Cited by 84
“We crossed P48Cre: LSLKras:INK4A mice, which develop PDAC (Aguirre et al., 2003), to SPARC and SPARC mice.”
InfluentialPIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
Payne, S. N., Maher, M. E., Tran, N. H., Van De Hey, D. R., Foley, T. M., Yueh, A. E., Leystra, A. A., Pasch, C. A., Jeffrey, J. J., Clipson, L., et al. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.28 · Cited by 72
Mouse models of pancreatic cancer
Leach, S. D. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00337-4 · Cited by 85
Kimura, K., Satoh, K., Kanno, A., Hamada, S., Hirota, M., Endoh, M., Masamune, A., & Shimosegawa, T. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00369.x · Cited by 81
Crawford, H. C., di Magliano, M. P., & Banerjee, S. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.042 · Cited by 77
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
Marsh Durban, V., Deuker, M. M., Bosenberg, M. W., Phillips, W., & McMahon, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69619 · Cited by 71
“Consequently, we employed a Cre-inactivated allele of Cdkn2a in conjunction with the genetic manipulations described above to first generate BRAF V600E /PTEN Null / CDKN2A Null or BRAF V600E /PIK3CA H1047R /CDKN2A Null melanomas from which cell lines were derived as described in the Methods (40).”
Pancreatic Cancer‐Induced Cachexia Is Jak2‐Dependent in Mice
Gilabert, M., Calvo, E., Airoldi, A., Hamidi, T., Moutardier, V., Turrini, O., & Iovanna, J. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24580 · Cited by 70
“In this paper, we demonstrated that pancreatic cancer-dependent cachexia induces Jak2-dependent pathway in all 3 tissues analyzed, we confirmed its activation in cachectic adipose tissue by immunohistochemistry using the anti-phospho-Jak2, and more importantly we were able to inhibit the cachexia progression by treati…”
MethodInfluentialFoygel, K., Wang, H., Machtaler, S., Lutz, A. M., Chen, R., Pysz, M. A., Lowe, A. W., Tian, L., Carrigan, T., Brentnall, T. A., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.011 · Cited by 69
BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer
Chiou, S.-H., Risca, V. I., Wang, G. X., Yang, D., Grüner, B. M., Kathiria, A. S., Ma, R. K., Vaka, D., Chu, P., Kozak, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0250 · Cited by 70
Gysin, S., Rickert, P., Kastury, K., & McMahon, M. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20216 · Cited by 73
“However, it should be noted that not all genetic abnormalities observed in human pancreas cancer have been recapitulated in the mouse model of this disease (Aguirre et al., 2003; Hingorani et al., 2003).”
BackgroundK-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
Hofmann, I., Weiss, A., Elain, G., Schwaederle, M., Sterker, D., Romanet, V., Schmelzle, T., Lai, A., Brachmann, S. M., Bentires-Alj, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044146 · Cited by 69
Pancreatic cancer–associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation
Gore, A. J., Deitz, S. L., Palam, L. R., Craven, K. E., & Korc, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71526 · Cited by 69
“PanIN are an important feature of PDAC initiation in both humans and GEMs, and PanIN progression to mPDAC is accelerated by deletion of the p53 (16), p16Ink4a/p19Arf (Cdkn2a) (17), Smad4 (15), p16Ink4a (19), and RB (18) tumor suppressors.”
Inhibition of Ras–effector interactions by cyclic peptides
Wu, X., Upadhyaya, P., Villalona-Calero, M. A., Briesewitz, R., & Pei, D. (2013) · MedChemComm · doi:10.1039/c2md20329d · Cited by 68
Tateishi, K., Ohta, M., Kanai, F., Guleng, B., Tanaka, Y., Asaoka, Y., Tada, M., Seto, M., Jazag, A., Lianjie, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0449 · Cited by 69
“Importantly, gene-targeting analysis has shown that p16 suppression is indispensable for invasive cancer formation (6).”
BackgroundDhar, G., Mehta, S., Banerjee, S., Gardner, A., McCarty, B. M., Mathur, S. C., Campbell, D. R., Kambhampati, S., & Banerjee, S. K. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.012 · Cited by 72
Metabolic Alterations in Pancreatic Cancer Progression
Vernucci, E., Abrego, J., Gunda, V., Shukla, S. K., Dasgupta, A., Rai, V., Chaika, N. V., Buettner, K. B., Illies, A. L., Yu, F., et al. (2019) · Cancers · doi:10.3390/cancers12010002 · Cited by 77
“To recapitulate the aggressive disease, the KC model was further modified to carry alterations or deletions in tumor suppressors, including p53 [7], SMAD4 [17], and p16 [6].”
BackgroundMethodGenetics and Genetic Testing in Pancreatic Cancer
Whitcomb, D. C., Shelton, C. A., & Brand, R. E. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.057 · Cited by 74
Erstad, D. J., Sojoodi, M., Taylor, M. S., Jordan, V. C., Farrar, C. T., Axtell, A. L., Rotile, N. J., Jones, C. M., Graham‐O'Regan, K. A., Ferreira, D. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1359 · Cited by 73
“13) from Ptf1a-Cre; LSLKras-G12D; p53 flox/þ mice on an inbred FVB/n background was used to generate tumors (27, 28).”
MethodSelf-citationZhang, X., Detering, L., Sultan, D. H., Luehmann, H. P., Li, L., Heo, G. S., Zhang, X., Lou, L., Grierson, P. M., Greco, S., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c08185 · Cited by 70
Emerging strategies to investigate the biology of early cancer
Zhou, R., Tang, X., & Wang, Y. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00754-y · Cited by 78
Esposito, I., Seiler, C., Bergmann, F., Kleeff, J. H., Friess, H., & Schirmacher, P. (2007) · Pancreas · doi:10.1097/mpa.0b013e31805d0190 · Cited by 77
“Autopsy series after 3, 4, 5, and 6 weeks revealed a progression from low- to high-grade PanIN lesions.(14) Older KRAS mice showed a replacement of the acinar parenchyma by metaplastic ducts, associated with an extensive fibroinflammatory reaction.”
BackgroundPre-Invasive Ovarian Mucinous Tumors Are Characterized by CDKN2A and RAS Pathway Aberrations
Hunter, S. M., Gorringe, K. L., Christie, M., Rowley, S. M., Bowtell, D. D. L., Chenevix‐Trench, G., & Campbell, I. G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1103 · Cited by 69
“metastatic neoplasms, compared with no neoplasms or localized neoplasms with individual mutations alone (52).”
BackgroundMameishvili, E., Serafimidis, I., Iwaszkiewicz, S., Lesche, M., Reinhardt, S., Bölicke, N., Büttner, M., Stellas, D., Papadimitropoulou, A., Szabolcs, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901075116 · Cited by 73
“Since the demonstration that a Pdx1-Cre– or Ptf1a-Cre–driven expression of Kras in all embryonic pancreas progenitor cells is sufficient to induce pancreatic cancer (3, 6), several Cre drivers have been used to identify adult cell populations that can undergo Kras*-driven oncogenic transformation.”
BackgroundGenetics and Biology of Pancreatic Ductal Adenocarcinoma
Dunne, R. F., & Hezel, A. F. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.003 · Cited by 66
Epithelial-to-Mesenchymal Transition in Pancreatic Adenocarcinoma
Cano, C. E., Motoo, Y., & Iovanna, J. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.183 · Cited by 77
“Combination of the Pdx1-Kras G12D allele with deletions of either p53 or p16/p19Ink4a lead to full development of pancreatic tumors, with a 100% penetrance and lethality within 12 weeks[23,30,31].”
BackgroundVariation in Precursor Lesions of Pancreatic Cancer among High-Risk Groups
Potjer, T. P., Schot, I., Langer, P., Heverhagen, J. T., Wasser, M. N. J. M., Slater, E. P., Klöppel, G., Morreau, H. M., Bonsing, B. A., de Vos tot Nederveen Cappel, W. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2730 · Cited by 67
“IPMNs were lacking in the pancreas of genetically engineered mice with K-RAS and p16 germline mutations (28) Taken together these data show that the results of the current”
BackgroundOstapoff, K. T., Awasthi, N., Cenik, B. K., Hinz, S., Dredge, K. S., Schwarz, R. E., & Brekken, R. A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1123 · Cited by 74
“LSL-Kras; Cdkn2a; p48 (mPDAC)mice (27, 28)weregenotyped shortly after birth and randomized to receive saline (control), Gem”
MethodBMI1 and MEL18 Promote Colitis-Associated Cancer in Mice via REG3B and STAT3
Liu, X., Wei, W., Li, X., Shen, P., Ju, D., Wang, Z., Zhang, R., Yang, F., Chen, C., Cao, K., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.044 · Cited by 71
Ponz‐Sarvisé, M., Corbo, V., Tiriac, H., Engle, D. D., Frese, K. K., Oni, T. E., Hwang, C., Öhlund, D., Chio, I. I. C., Baker, L. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1398 · Cited by 69
Self-citationTu, Q., Hao, J., Zhou, X., Yan, L., Dai, H., Sun, B., Yang, D., An, S., Lv, L., Jiao, B., et al. (2018) · Oncogene · doi:10.1038/onc.2017.316 · Cited by 66
Aberrant signaling pathways in pancreatic cancer: A two compartment view
McCleary‐Wheeler, A. L., McWilliams, R. R., & Fernández-Zapico, M. E. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20827 · Cited by 87
“This is achieved by crossing the LSL-KrasG12D/þ mice to pdx1-Cre or p48-Cre mice [35,36].”
MethodPalamaris, K., Felekouras, E. S., & Sakellariou, S. (2021) · Cancers · doi:10.3390/cancers13215532 · Cited by 76
“[72], cerulein and duct ligation induced pancreatitis accelerated the emergence of ADM and PanIN in PKC and IKC mouse strains, and led to a higher proportion of cells undergoing EMT, invading the surround‐ Figure 1.”
MethodInfluentialOncogenic Ras/Src cooperativity in pancreatic neoplasia
Shields, D. J., Murphy, E. A., Desgrosellier, J. S., Mielgo, A., Lau, S. K. M., Barnes, L. A., Lesperance, J., Huang, M., Schmedt, C., Tarin, D., et al. (2011) · Oncogene · doi:10.1038/onc.2010.589 · Cited by 64
“Pancreatic tumor cell lines PDA cell lines were isolated as described (Aguirre et al., 2003) from primary tumors in the Kras/Src model.”
BackgroundMethodHu, C., Dadon, T., Chenna, V., Yabuuchi, S., Bannerji, R., Booher, R., Strack, P., Azad, N., Nelkin, B. D., & Maitra, A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0028 · Cited by 64
“org Mol Cancer Ther; 14(7) July 2015 1535”
BackgroundInfluentialMayrhofer, M., Gourain, V., Reischl, M., Affaticati, P., Jenett, A., Joly, J., Benelli, M., Demichelis, F., Poliani, P. L., Sieger, D., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.026500 · Cited by 81
“The progression of pre-malignant developmental lesions to tumours has been proved for several tissues such as colon (Macrae et al., 2009) and pancreas (Aguirre et al., 2003).”
Neoplasms of the Exocrine Pancreas
Wolff, R. A., Crane, C. H., Li, D., Evans, D. B., Maitra, A., & Tsai, S. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm094 · Cited by 64
Ischenko, I., Petrenko, O., & Hayman, M. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319911111 · Cited by 64
“The first mouse models of PDAC were generated by combining KrasG12D activation in embryonic pancreatic progenitors (using the PDX1 promoter) with homozygous deletion of p53 or CDKN2A (1, 2, 26).”
BackgroundMethodInfluentialInterplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
Liu, Y.-H., Hu, C., Hsu, Y.-S., & Lee, W. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05259-w · Cited by 77
“In addition, since KRASmutation alone is insufficient to generate PDAC [49, 50], specific pancreatic cells containing KRAS mutations may require additional alterations to exhibit subtle phenotypic changes at the beginning.”
BackgroundBarceló, C., Etchin, J., Mansour, M. R., Sanda, T., Morell, M., Lobo, V. J. S.-A., Real, F. X., Capellá, G., Estanyol, J. M., Jaumot, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.041 · Cited by 68
A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer
Zhao, X., Wang, X., Fang, L., Lan, C., Zheng, X., Wang, Y., Zhang, Y., Han, X., Liu, S., Cheng, K., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.015 · Cited by 67
Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous
Chung, W.-J., Daemen, A., Cheng, J. H., Long, J. E., Cooper, J. E., Wang, B.-E., Tran, C., Singh, M., Gnad, F., Modrusan, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708391114 · Cited by 63
“; Anton Berns (Netherlands Cancer Institute, Amsterdam); and Andy Lowy (University of San Diego, San Diego) (13, 14, 30, 31).”
BackgroundDeciphering DNA methylation signatures of pancreatic cancer and pancreatitis
Natale, F., Vivo, M., Falco, G., & Angrisano, T. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0728-8 · Cited by 69
In vivo disruption of TGF-β signaling by Smad7 leads to premalignant ductal lesions in the pancreas
Kuang, C., Xiao, Y., Liu, X., Stringfield, T. M., Zhang, S., Wang, Z., & Chen, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508977103 · Cited by 68
Herting, C. J., Karpovsky, I., & Lesinski, G. B. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09988-w · Cited by 69
Oncogenic K-ras cooperates with PML-RAR to induce an acute promyelocytic leukemia-like disease
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Moore, S., Shigematsu, H., Ley, T. J., Akashi, K., Beau, M. M. L., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2006-04-015040 · Cited by 67
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zhang, Z., Zhang, H., Liao, X., & Tsai, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147676 · Cited by 82
“Single Ink4a/Arf loss has no effect on tumor lesions but leads to their rapid progression to highly invasive and metastatic pancreatic adenocarcinoma in the presence of KRAS (Aguirre et al., 2003).”
BackgroundWirth, M., Stojanovic, N., Christian, J. G., Paul, M. C., Stauber, R. H., Schmid, R. M., Häcker, G. A., Krämer, O. H., Saur, D., & Schneider, G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku763 · Cited by 64
“To investigate the contribution of ARF, we generated a murine pancreatic cancer cell line from a Ptf1aCre/+; LSL-KrasG12D/+; Cdkn2alox/lox;R26LSL-TVA-LacZ/+ mouse, PPT-AA728.”
MethodAmplification-free digital gene expression profiling from minute cell quantities
Ozsolak, F., Ting, D. T., Wittner, B. S., Brannigan, B. W., Paul, S., Bardeesy, N., Ramaswamy, S., Milos, P. M., & Haber, D. A. (2010) · Nature Methods · doi:10.1038/nmeth.1480 · Cited by 59
Self-citationDonahue, K. L., Watkoske, H. R., Kadiyala, P., Du, W., Brown, K. L., Scales, M. K., Elhossiny, A. M., Espinoza, C. E., Opsahl, E. L. L., Griffith, B. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0100 · Cited by 64
“pancreas-specific expression of KRAS G12D drives the transformation of healthy tissue into premalignant precursor lesions known as pancreatic intraepithelial neoplasia (PanIN), which progress over time into invasive PDA (5, 6).”
Modelling oncogenic Ras/Raf signalling in the mouse
Karreth, F. A., & Tuveson, D. A. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.12.006 · Cited by 59
Self-citationSOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms
Shroff, S. G., Rashid, A., Wang, H., Katz, M. H. G., Abbruzzese, J. L., Fleming, J. B., & Wang, H. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.10.008 · Cited by 68
Ostapoff, K. T., Cenik, B. K., Wang, M., Ye, R., Xu, X., Nugent, D., Hagopian, M. M., Topalovski, M., Rivera, L. B., Carroll, K. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1807 · Cited by 60
Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer
Grimont, A., Leach, S. D., & Chandwani, R. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.014 · Cited by 68
Molecular Characteristics of Pancreatic Ductal Adenocarcinoma
Ottenhof, N. A., de Wilde, R. F., Maitra, A., Hruban, R. H., & Offerhaus, G. J. A. (2011) · Pathology Research International · doi:10.4061/2011/620601 · Cited by 71
Mouse Models of Human Non-Small-Cell Lung Cancer: Raising the Bar
KIM, C. F. B., JACKSON, E. L., KIRSCH, D. G., GRIMM, J., SHAW, A. T., LANE, K., KISSIL, J., OLIVE, K. P., SWEET-CORDERO, A., WEISSLEDER, R., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.037 · Cited by 58
Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer
Kemp, S. B., Pasca di Magliano, M., & Crawford, H. C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.006 · Cited by 55
Feldmann, G., & Maitra, A. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070115 · Cited by 66
Ras Activity in Acinar Cells Links Chronic Pancreatitis and Pancreatic Cancer
Logsdon, C. D., & Ji, B. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.040 · Cited by 57
Pancreatic Intraepithelial Neoplasia and Pancreatic Tumorigenesis: Of Mice and Men
Ottenhof, N. A., Milne, A. N., Morsink, F. H. M., Drillenburg, P., ten Kate, F. J. W., Maitra, A., & Offerhaus, G. J. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.3.375 · Cited by 63
KRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 73
“However, when mutant Kras was combined with inactivation of the Trp53 (36), Ink4a/Arf (37), or Smad4 (38) tumor suppressor genes, it resulted in rapid progression of PanINs and fully penetrant development of invasive and highly metastatic PDAC.”
Molecular pathology of pancreatic cancer
Saiki, Y., & Horii, A. (2014) · Pathology International · doi:10.1111/pin.12114 · Cited by 57
Ali, S. S., Banerjee, S., Logna, F., Bao, B., Philip, P. A., Korc, M., & Sarkar, F. H. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.24036 · Cited by 56
“Hence several mouse models have been created to mimic human PC that has been proven useful for studying tumor progression, prevention, and therapy (Aguirre et al., 2003; Hingorani et al., 2003, 2005; Tuveson and Hingorani, 2005; Frese and Tuveson, 2007; Cook et al., 2008; Olive et al., 2009;…”
BackgroundRetractedThe Survival Kinase Mirk/Dyrk1B Is a Downstream Effector of Oncogenic K-ras in Pancreatic Cancer
Jin, K., Park, S., Ewton, D. Z., & Friedman, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4099 · Cited by 62
“Studies employing mice engineered to exhibit pancreas-specific Cre-mediated activation of a mutant Kras allele (K-rasG12D) have clearly shown that physiologic levels of mutant K-ras induce the full spectrum of PanINs found in humans (26, 27).”
BackgroundRachagani, S., Macha, M. A., Menning, M., Dey, P., Pai, P., Smith, L. M., Mo, Y.-Y., & Batra, S. K. (2015) · Oncotarget · doi:10.18632/oncotarget.5641 · Cited by 60
“Due to unavailability of early stage samples from human PC patients, we utilized the well-characterized spontaneous mouse model (KC) of PC [32–36] to analyze the global miRNA expression profile.”
Telomere function and regulation from mouse models to human ageing and disease
Jones-Weinert, C. W., Mainz, L., & Karlseder, J. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00800-5 · Cited by 68
“By contrast, mouse cells may require only the p53–p21 pathway to launch TIF-induced senescence 20,194,195 , but still rely on both checkpoint pathways for genome-wide DNA damage-induced senescence 196,197 .”
Qu, D., Johnson, J., Chandrakesan, P., Weygant, N., May, R. J., Aiello, N. M., Rhim, A. D., Zhao, L., Zheng, W., Lightfoot, S. A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118933 · Cited by 58
“The KPC mouse line is a well-established mouse line for pancreatic cancer model [25,31].”
BackgroundErlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals
Miyabayashi, K., Ijichi, H., Mohri, D., Tada, M., Yamamoto, K., Asaoka, Y., Ikenoue, T., Tateishi, K., Nakai, Y., Isayama, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1453 · Cited by 61
Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes
Villasenor, A., Wang, Z. V., Rivera, L. B., Ocal, O., Asterholm, I. W., Scherer, P. E., Brekken, R. A., Cleaver, O., & Wilkie, T. M. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.003210 · Cited by 55
“…expression in surrogates of pancreatic ducts and/or endocrine progenitors, such as primary cultured cells from pancreatic ductal adenocarcinoma (Aguirre et al., 2003), ‘endocrine-differentiated’ embryonic stem (ES) cells (Kroon et al., 2008; Serafimidis et al., 2008), or induced pluripotent…”
BackgroundMorphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs)
Koorstra, J.-B. M., Feldmann, G., Habbe, N., & Maitra, A. (2008) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-008-0282-x · Cited by 83
“On the other hand, abrogation of either INK4a/Arf or TP53 signaling alone in the absence of oncogenic Kras does not lead to the development of pancreatic carcinomas or associated precursor lesions, underscoring the crucial importance of Kras signaling in initiating the cascade of events, which result in pancreatic car…”
BackgroundTumour neoantigen mimicry by microbial species in cancer immunotherapy
Boesch, M., Baty, F., Rothschild, S. I., Tamm, M., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01365-2 · Cited by 58
Pre-clinical Models of Metastasis in Pancreatic Cancer
Miquel, M., Zhang, S., & Pilarsky, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748631 · Cited by 53
“Aguirre (2003) showed that homozygous deletion of Cdkn2a in the context of Kras mutation in the pancreas (KrasLSL.”
BackgroundGrasso, D., Garcia, M. N., Hamidi, T., Cano, C. E., Calvo, E. L., Lomberk, G. A., Urrutia, R. A., & Iovanna, J. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.74 · Cited by 55
“The Pdx1-cre;LSL-Kras mice were provided by R Depinho (Dana-Faber Cancer Institute, Boston, MA, USA) and resulted from crossbreeding of the following strains: Pdx1-Cre(31) and LSL-Kras.(32) Pancreatitis was induced by intraperitoneal administration of cerulein (Sigma-Aldrich, St.”
MethodPAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis
Jun, S., Lee, S., Kim, H.-C., Ng, C., Schneider, A. M., Ji, H. L., Ying, H., Wang, H., DePinho, R. A., & Park, J. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.026 · Cited by 75
“DISCUSSION The prevailing view of pancreatic cancer models is that the constitutive activation of K-Ras/ MAPK signaling leads to hyperproliferation and transformation of pancreatic ductal epithelial cells (Aguirre et al., 2003; Hingorani et al., 2003).”
BackgroundInfluentialSelf-citationVorvis, C., Hatziapostolou, M., Mahurkar‐Joshi, S., Κουτσιούμπα, Μ., Williams, J. L., Donahue, T. R., Poultsides, G. A., Eibl, G., & Iliopoulos, D. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2016 · Cited by 58
“4 TP53, and SMAD4 that are inactivated in more than 50% of all pancreatic cancers (1, 30, 31, 58).”
New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis
Felsenstein, M., Hruban, R. H., & Wood, L. D. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000172 · Cited by 63
A genetic roadmap of pancreatic cancer: still evolving
Notta, F., Hahn, S. A., & Real, F. X. (2017) · Gut · doi:10.1136/gutjnl-2016-313317 · Cited by 61
Müller‐Decker, K., Fürstenberger, G., Annan, N., Kucher, D., Pohl–Arnold, A., Steinbauer, B., Esposito, I., Chiblak, S., Friess, H., Schirmacher, P., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.053 · Cited by 57
Sempere, L. F., Gunn, J. R., & Korc, M. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.3.15979 · Cited by 52
“An advantage of these murine PCCs is that they have a well-defined mutation history, largely dependent on the genetically-engineered activation of mutated K-Ras and/or loss of tumor suppressor genes.(26,27) This panel f human and murine PCCs was used for the studies described below.”
MethodMenezes, M. E., Das, S. K., Minn, I., Emdad, L., Wang, X.-Y., Sarkar, D., Pomper, M. G., & Fisher, P. B. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.07.001 · Cited by 61
“Another example is transgenic mice expressing KrasG12D with Ink4a/Arf deficiency specifically in the pancreas (Aguirre et al., 2003).”
BackgroundEpithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice
Zhang, Y., Yan, W., Mathew, E., Kane, K. T., Brannon, A., Adoumie, M., Vinta, A., Crawford, H. C., & Pasca di Magliano, M. (2017) · eLife · doi:10.7554/elife.27388 · Cited by 52
“DOI: https://doi.org/10.7554/eLife.27388 1 of 24 pancreatic cancer (Aguirre et al., 2003; Hingorani et al., 2003; Hingorani et al., 2005), a process that is accelerated by the introduction of other common mutations, such as mutation or loss of tumor suppressors p53 and Ink4a/ARF (Aguirre et al., 2003; Hingorani et al.…”
BackgroundInfluentialPrecancer in Mice: Animal Models Used to Understand, Prevent, and Treat Human Precancers
Cardiff, R. D., Anver, M. R., Boivin, G. P., Bosenberg, M., Maronpot, R. R., Molinolo, A., Nikitin, A. Y., Rehg, J. E., THOMAS, G. V., Russell, R. G., et al. (2006) · Toxicologic Pathology · doi:10.1080/01926230600930129 · Cited by 55
“Two mouse models that develop mPanIN have recently been developed (Aguirre et al., 2003; Hingorani et al., 2003).”
BackgroundYan, W., Menjivar, R. E., Bonilla, M. E., Steele, N. G., Kemp, S. B., Du, W., Donahue, K. L., Brown, K. L., Carpenter, E. S., Avritt, F. R., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0037 · Cited by 54
Pancreatic cancer organotypic cultures
Froeling, F. E. M., Marshall, J. F., & Kocher, H. M. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.01.008 · Cited by 58
Cancer mouse models: Past, present and future
Khaled, W. T., & Liu, P. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.04.003 · Cited by 60
Role of metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) in pancreatic cancer
Cheng, Y., Imanirad, P., Jutooru, I., Hedrick, E., Jin, U.-H., Hoffmann, A. R., de Araújo, J. L., Morpurgo, B., Golovko, A., & Safe, S. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192264 · Cited by 56
“Using founder mice provided by the DePinho laboratory [46,47], we generated p53L/L;LSL-Kras G12D L/+; p48Cre+/- (p53 L/L /Kras G12D ) and p53L/+;LSLKras G12D L/+;p48Cre+/- (p53 L/+ /Kras G12D ) mice which are p53 homo-and heterozygous, respectively.”
Cooperativity of Oncogenic K-Ras and Downregulated p16/INK4A in Human Pancreatic Tumorigenesis
Chang, Z., Ju, H., Ling, J., Zhuang, Z., Li, Z., Wang, H., Fleming, J. B., Freeman, J. W., Yu, D., Huang, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101452 · Cited by 52
“To recapitulate the molecular pathogenesis of this disease, several experimental animal models have been established recently to determine the functions of mutated K-ras and inactivated p16 in pancreatic tumorigenesis [6,7].”
Wang, Z. P., Ali, S. S., Banerjee, S., Bao, B., Li, Y., Azmi, A. S., Korc, M., & Sarkar, F. H. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24162 · Cited by 50
“Moreover, previous report has shown that KCI mice have metastasis to multiple organ sites (Aguirre et al., 2003), suggesting that the tumors developed in the KCI mice is highly aggressive.”
BackgroundRetractedMathew, E., Collins, M. A., Fernandez-Barrena, M. G., Holtz, A. M., Yan, W., Hogan, J. O., Tata, Z., Allen, B. L., Fernandez-Zapico, M. E., & Pasca di Magliano, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.556563 · Cited by 50
“In mice, pancreatic cancer can be modeled by expressing oncogenic Kras in the pancreas epithelium (6, 7).”
BackgroundA Case of Mistaken Identity? Nonductal Origins of Pancreatic “Ductal” Cancers
Murtaugh, L. C., & Leach, S. D. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.020 · Cited by 54
Interactions of circadian clock genes with the hallmarks of cancer
Ortega-Campos, S. M., Verdugo‐Sivianes, E. M., Amiama-Roig, A., Blanco, J. R., & Carnero, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188900 · Cited by 63
Inflammation and pancreatic cancer: disease promoter and new therapeutic target
Hamada, S., Masamune, A., & Shimosegawa, T. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0915-x · Cited by 57
“invasive pancreatic cancer [31, 32].”
Molecular Events in Follicular Thyroid Tumors
Kroll, T. G. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-8107-3_4 · Cited by 50
BRAF Activation Initiates but Does Not Maintain Invasive Prostate Adenocarcinoma
Jeong, J. H., Wang, Z., Guimarães, A. R., Ouyang, X., de Figueiredo, J. L., Ding, Z., Jiang, S., Guney, I., Kang, G. H., Shin, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003949 · Cited by 52
“Immunohistochemistry were performed as described previously[45].”
MethodInfluential
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.